Environmental risk assessment of anti-cancer drugs and their transformation products: A focus on their genotoxicity characterization-state of knowledge and short comings

Mutation Research - Reviews in Mutation Research

Volumn 760, Issue , 2014, Pages 18-35

  Toolaram, Anju Priya ^a   Kümmerer, Klaus ^a   Schneider, Mandy ^a  

^a LEUPHANA UNIVERSITY OF LÜNEBURG   (Germany)

Author keywords

Anti cancer drug; Environment; Mixture toxicity; Mutagenicity; Risk assessment; Transformation product

Indexed keywords

ANTINEOPLASTIC AGENT; ENVIRONMENTAL CHEMICAL;

AMES TEST; AQUATIC ENVIRONMENT; BIOASSAY; BIODEGRADABILITY; COMPUTER ANALYSIS; ENVIRONMENTAL DISEASE; ENVIRONMENTAL IMPACT; ENVIRONMENTAL IMPACT ASSESSMENT; GENOTOXICITY; HOSPITAL WASTE; METABOLITE; PREDICTION; PRIORITY JOURNAL; QUANTITATIVE STRUCTURE ACTIVITY RELATION; REVIEW; RISK ASSESSMENT; WASTE WATER;

EID: 84900419090     PISSN: 13835742     EISSN: 13882139     Source Type: Journal    
DOI: 10.1016/j.mrrev.2014.02.001     Document Type: Review

References (104)

1. International Agency for Research on Cancer (IARC), GLOBOCAN 2008 FAST STATS, 2013.
2. Mosby's Medical Dictionary, 8th ed., Mosby, St. Louis, MO, 2009.
3. International Agency for Research on Cancer (IARC) IARC Monographs on the Evaluation of Carcinogenic Risk of Chemicals to Humans: Some Antineoplastic and Immunosuppressive Agents 1981, vol. 26. IARC, Lyon.
4. Allwood M., Stanley A., Wright P. The Cytotoxics Handbook 2002, Oxford Radcliffe Medical Press. 4th ed.
5. Falck K., Gröhn P., Sorsa M., Vainio H., Heinonen E., Holsti L.R. Mutagenicity in urine of nurses handling cytotoxic drugs. Lancet 1979, 1:1250-1251.
6. Machado-Santelli G.M., Cerqueira E.M., Oliveira C.T., Pereira C.A. Biomonitoring of nurses handling antineoplastic drugs. Mutat. Res. 1994, 322(3):203.
7. Fucic A., Jazbec A., Mijic A., Seso-Simic D., Tomek R. Cytogenetic consequences after occupational exposure to antineoplastic drugs. Mutat. Res. 1998, 416(1-2):59.
8. Burgaz S., Karahalil B., Canhi Z., Terzioglu F., Ançel G., Anzion R.B.M., Bos R.P., et al. Assessment of genotoxic damage in nurses occupationally exposed to antineoplastics by the analysis of chromosomal aberrations. Hum. Exp. Toxicol. 2002, 21(3):129.
9. Rekhadevi P.V., Sailaja N., Chandrasekhar M., Mahboob M., Rahman M.F., Grover P. Genotoxicity assessment in oncology nurses handling anti-neoplastic drugs. Mutagenesis 2007, 22(6):395.
10. Johnson A.C., Jürgens M.D., Williams R.J., Kümmerer K., Kortenkamp A., Sumpter J.P. Do cytotoxic chemotherapy drugs discharged into rivers pose a risk to the environment and human health? An overview and UK case study. J. Hydrol. 2008, 348(1-2):167.
11. Richardson M.L., Bowron J.M. The fate of pharmaceutical chemicals in the aquatic environment. J. Pharm. Pharmacol. 1985, 37(1):1.
12. Daughton C.G., Ruhoy I.S. Environmental footprint of pharmaceuticals: the significance of factors beyond direct excretion to sewers. Environ. Toxicol. Chem. 2009, 28(12):2495.
13. Kosjek T., Heath E. Occurrence, fate and determination of cytostatic pharmaceuticals in the environment. Biogenic Volatile Org. Compd. S.I. 2011, 30(7):1065.
14. Aherne G.W., Hardcastle A., Nield A.H. Cytotoxic drugs and the aquatic environment: estimation of bleomycin in river and water samples. J. Pharm. Pharmacol. 1990, 42(10):741.
15. Besse J.P., Latour J.F., Garric J. Anticancer drugs in surface waters: what can we say about the occurrence and environmental significance of cytotoxic, cytostatic and endocrine therapy drugs?. Environ. Int. 2012, 39(1):73.
16. Xie H. Occurrence, ecotoxicology, and treatment of anticancer agents as water contaminants. J. Environ. Anal. Toxicol. 2012, S2(002):1-11.
17. Zhang J., Chang V.W.C., Giannis A., Wang J.-Y. Removal of cytostatic drugs from aquatic environment: a review. Sci. Total Environ. 2013, 445-446:281.
18. Kümmerer K., Steger-Hartmann T., Baranyai A., Bürhaus I. Untersuchung des Abbaus der Zytostatika Ifosfamid und Cyclophosphamid mit dem Closed Bottle test (OECD 301). Zentralblatt für Hygiene und Umweltmedizin 1996, 198(3):215.
19. Kümmerer K., Steger-Hartmann T., Meyer M. Biodegradability of the anti-tumour agent ifosfamide and its occurrence in hospital effluents and communal sewage. Water Res. 1997, 31(11):2705.
20. Kümmerer K., Al-Ahmad A., Mersch-Sundermann V. Biodegradability of some antibiotics, elimination of the genotoxicity and affection of wastewater bacteria in a simple test. Chemosphere 2000, 40(7):701.
21. Kümmerer K., Al-Ahmad A. Biodegradability of the anti-tumour agents 5-fluorouracil, cytarabine, and gemcitabine: impact of the chemical structure and synergistic toxicity with hospital effluent. Acta Hydrochim. Hydrobiol. 1997, 25(4):166.
22. Al-Ahmad A., Kümmerer K., Schön G. Biodegradation and toxicity of the antineoplastics mitoxantron hydrochloride and treosulfane in the Closed Bottle Test (OECD 301 D). Bull. Environ. Contam. Toxicol. 1997, 58(5):704.
23. Steger-Hartmann T., Kümmerer K., Schecker J. Trace analysis of the antineoplastics ifosfamide and cyclophosphamide in sewage water by twostep solid-phase extraction and gas chromatography-mass spectrometry. J. Chromatogr. A 1996, 726(1-2):179.
24. Steger-Hartmann T., Kümmerer K., Hartmann A. Biological degradation of cyclophosphamide and its occurrence in sewage water. Ecotoxicol. Environ. Saf. 1997, 36(2):174.
25. Al-Ahmad A., Kümmerer K. Biodegradation of the antineoplastics vindesine, vincristine, and vinblastine and their toxicity against bacteria in the aquatic environment. Cancer Detect. Prev. 2001, 25(1):102.
26. The Anatomical Therapeutic cöassification system: L Antineoplastics and Immunomodulating Agents, Available at: , Accessed on 02/2013. http://www.whocc.no/atc_ddd_index/%3Fcode=L01%26showdescription=no.
27. Ferguson L.R., Denny W.A. Anticancer drugs: an underestimated risk or an underutilised resource in mutagenesis?. Mutat. Res. 1995, 331(1):1.
28. Beck W.T., Cass C.E., Houghton P.J. Microtubule-targeting anticancer drugs derived from plants and microbes: vinca alkaloids, taxanes, and epothilones. Holland-Frei Cancer Medicine 2000, BC Decker, Hamilton (ON), Chapter 50. 5th ed. R.C. Bast, D.W. Kufe, R.E. Pollock (Eds.).
29. Cohen M.H., Williams G., Johnson J.R., Duan J., Gobburu J., Rahman A., Benson K., et al. Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia. Clin. Cancer Res. 2002, 8(5):935.
30. A. Bergmann, R. Fohrmann, F. Weber, Zusammenstellung von Monitoringdaten zu Umweltkonzentrationen von Arzneimitteln, UmweltBundesamt, Dessau-Roßlau, 2011.
31. Bagley A.M., Bostick F.W., DeVita V.T. Clinical pharmacology of cyclophosphamide. Cancer Res. 1973, 33(2):226.
32. Heggie G.D., Sommadossi J.P., Cross D.S., Huster W.J., Diasio R.B. Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile. Cancer Res. 1987, 47(8):2203.
33. K. Kümmerer, A. Schuster, A. Haiss, A. Günther, J. Jacobs, Umweltrisikobewertung von Zytostatika, UmweltBundesamt, Dessau-Roßlau, 2009.
34. European Medicines Agency (EMA), Guideline on the environmental risk assessment of medicinal products for human use 2006, Available at: , Accessed on: 01/2013. http://www.ema.europa.eu/ema/pages/includes/document/open_document.jsp%3FwebContentId=WC500003978.
35. Food and Drug Administration (FDA), Guidance for Industry Environmental Assessment of Human Drug and Biologics Applications 1998, Available at: , Accessed on: 01/2013. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm070561.pdf.
36. Johnson A.C., Oldenkamp R., Dumont E., Sumpter J.P. Predicting concentrations of the cytostatic drugs cyclophosphamide, carboplatin, 5-fluorouracil, and capecitabine throughout the sewage effluents and surface waters of Europe. Environ. Toxicol. Chem. 2013, 32(9):1954.
37. Jjemba P.K. Pharma-ecology: the Occurrence and Fate of Pharmaceuticals and Personal Care Products in the Environment 2008, Wiley, Hoboken, NJ.
38. Buerge I.J., Buser H.-R., Poiger T., Müller M.D. Occurrence and fate of the cytostatic drugs cyclophosphamide and ifosfamide in wastewater and surface waters. Environ. Sci. Technol. 2006, 40(23):7242.
39. Zuccato E., Castiglioni S., Fanelli R., Reitano G., Bagnati R., Chiabrando C., Pomati F., et al. Pharmaceuticals in the environment in Italy: causes, occurrence, effects and control. Envion. Sci. Pollut. Res. Int. 2006, 13(1):15-21.
40. Mahnik S.N., Lenz K., Weissenbacher N., Mader R.M., Fuerhacker M. Fate of 5-fluorouracil, doxorubicin, epirubicin, and daunorubicin in hospital wastewater and their elimination by activated sludge and treatment in a membrane-bio-reactor system. Chemosphere 2007, 66(1):30.
41. Halling-Sørensen B., Nors Nielsen S., Lanzky P.F., Ingerslev F., Holten Lützhøft H.C., Jørgensen S.E. Occurrence, fate and effects of pharmaceutical substances in the environment-a review. Chemosphere 1998, 36(2):357.
42. Kovalova L., McArdell C.S., Hollender J. Challenge of high polarity and low concentrations in analysis of cytostatics and metabolites in wastewater by hydrophilic interaction chromatography/tandem mass spectrometry. J. Chromatogr. A 2009, 1216(7):1100.
43. Kiffmeyer T., Götze H., Jursch M., Lüders U. Trace enrichment, chromatographic separation and biodegradation of cytostatic compounds in surface water. Fresenius' J. Anal. Chem. 1998, 361(2):185.
44. Gartiser S., Brinker L., Erbe T., Kümmerer K., Willmund R. Belastung von Krankenhausabwasser mit gefährlichen Stoffen im Sinne § 7a WHG. Acta Hydrochim. Hydrobiol. 1996, 24(2):90.
45. Giuliani F., Koller T., Würgler F.E., Widmer R.M. Detection of genotoxic activity in native hospital waste water by the umuC test. Mutat. Res./Genet. Toxicol. 1996, 368(1):49.
46. Schulman L.J., Sargent E.V., Naumann B.D., Faria E.C., Dolan D.G., Wargo J.P. A human health risk assessment of pharmaceuticals in the aquatic environment. Hum. Ecol. Risk Assess. 2002, 8:657-680.
47. Webb S., Ternes T., Gibert M., Olejniczak K. Indirect human exposure to pharmaceuticals via drinking water. Toxicol. Lett. 2003, 142:157-167.
48. Janusinfo Stockholms Läans Lansting, Available at: http://www.janusinfo.se/Beslutsstod/Miljo-och-lakemedel/About-the-environment-and-pharmaceuticals/Environmentially-classified-pharmaceuticals/Antineoplastic-and-immunomodulating-agents//?id=12507#, Accessed on: 02/2013.
49. Schuster A., Hädrich C., Kümmerer K. Flows of active pharmaceutical ingredients originating from health care practices on a local, regional, and nationwide level in Germany: is hospital effluent treatment an effective approach for risk reduction?. Water Air Soil Pollut. 2008, 8(5-6):457-547.
50. I. Schirmer, Do transformation products pose environmental risks?: Eawag News no. 70, Healthy water resources-balancing the needs of humans and the environment 2011.
51. Ng A.A., Scheringer M., Fenner K., Hungerbuhler K. A framework for evaluating the contribution of transformation products to chemical persistence in the environment†. Environ. Sci. Technol. 2010, 45(1):111.
52. International Conference in Harmonisation of Technical Requirements of Pharmaqecuticals for Human Use (ICH), Guidance on Genotoxicity testing and data interpretation for pharmaceuticals intended for human use S2(R1) 2011, Available at: www.ich.org/fileadmin/. . ./ICH. . ./Guidelines/. . ./S2_R1/. . ./S2R1_Step4.pdf, Accessed on: 07/2013.
53. Nau H., Spielmann H., Lo Turco Morther C.M., Winckler K., Riedel L., Obe G. Mutagenic, teratogenic and pharmacokinetic properties of cyclophosphamide and some of its deuterated derivatives. Mutat. Res. Fund. and Mol. Mech. Mutag. 1982, 95(2-3):105.
54. Hales B.F. Comparison of the mutagenicity and teratogenicity of cyclophosphamide and its active metabolites, 4-hydroxycyclophosphamide, phosphoramide mustard, and acrolein. Cancer Res. 1982, 42(8):3016.
55. Winckler K., Obe G., Madle S., Nau H. Mutagenic activities of cyclophosphamide (NSC-26271) and its main metabolites in Salmonella typhimurium, human peripheral lymphocytes and Chinese hamster ovary cells. Mutat. Res./Fund. Mol. Mech. Mutag. 1984, 129(1):47.
56. Colvin I., Brundrett R.B., Kan M.-N.N., Jardine I., Fenselau C. Alkylating properties of phosphoramide mustard. Cancer Res. 1976, 36(3):1121.
57. Jha A.N. Genotoxicological studies in aquatic organisms: an overview. Genotoxicol. Stud. Aquat. Organ. 2004, 552(1-2):1.
58. Grisolia C.K., Cordeiro C.M.T. Variability in micronucleus induction with different mutagens applied to several species of fish. Genet. Mol. Biol. 2000, 23(1):235.
59. Al-Sabti K., Metcalfe C.D. Fish micronuclei for assessing genotoxicity in water. Mutat. Res. Genet. Toxicol. 1995, 343(2-3):121.
60. Grisolia C.K. A comparison between mouse and fish micronucleus test using cyclophosphamide, mitomycin C and various pesticides. Mutat. Res. Genet. Toxicol. Environ. Mutag. 2002, 518(2):145.
61. Sánchez P., Llorente M.T., Castaño A. Flow cytometric detection of micronuclei and cell cycle alterations in fish-derived cells after exposure to three model genotoxic agents: mitomycin C, vincristine sulfate and benzo(a)pyrene. Mutat. Res. 2000, 465(1-2):113.
62. Yasunaga K., Kiyonari A., Nakagawa M., Yoshikawa K. Investigation into the ability of the Salmonella umu test to detect DNA damage using antitumor drugs. Toxicol. Vitro 2006, 20(5):712.
63. Zounková R., Odráška P., Doležalová L., Hilscherová K., Maršálek B., Bláha L. Ecotoxicity and genotoxicity assessment of cytostatic pharmaceuticals. Environ. Toxicol. Chem. 2007, 26(10):2208.
64. Zounkova R., Kovalova L., Blaha L., Dott W. Ecotoxicity and genotoxicity assessment of cytotoxic antineoplastic drugs and their metabolites. Chemosphere 2010, 81(2):253.
65. Babich H., Borenfreund E. Cytotoxicity and genotoxicity assays with cultured fish cells: a review. Toxicol. Vitro 1991, 5(1):91.
66. Barek J., Castegnaro M., Malaveille C., Brouet I., Zima J. A method for the efficient degradation of melphalan into nonmutagenic products. Microchem. J. 1987, 36(2):192.
67. Lunn G., Sansone E.B., Andrews A.W., Hellwig L.C. Degradation and disposal of some antineoplastic drugs. J. Pharm. Sci. 1989, 78(8):652.
68. Benvenuto J.A., Connor T.H., Monteith D.K., Laidlaw J.L., Adams S.C., Matney T.S., Theiss J.C. Degradation and inactivation of antitumor drugs. J. Pharm. Sci. 1993, 82(10):988.
69. Hansel S., Castegnaro M., Sportouch M.H., de Méo M., Milhavet J.C., Laget M., Duménil G. Chemical degradation of wastes of antineoplastic agents: cyclophosphamide, ifosfamide and melphalan. Int. Arch. Occup. Environ. Health 1996, 69(2):109-114.
70. Castegnaro M., de Méo M., Laget M., Michelon J., Garren L., Sportouch M.H., Hansel S. Chemical degradation of wastes of antineoplastic agents. 2: Six anthracyclines: idarubicin, doxorubicin, epirubicin, pirarubicin, aclarubicin, and daunorubicin. Int. Arch. Occup. Environ. Health 1997, 70(6):378.
71. Barek J., Cvacka J., de Méo M., Laget M., Michelon J., Castegnaro M. Chemical degradation of wastes of antineoplastic agents amsacrine, azathioprine, asparaginase and thiotepa. Ann. Occup. Hyg. 1998, 42(4):259.
72. Lunn G., Rhodes S.W., Sansone E.B., Schmuff N.R. Photolytic destruction and polymeric resin decontamination of aqueous solutions of pharmaceuticals. J. Pharm. Sci. 1994, 83(9):1289.
73. Burleson G.R., Chambers T.M. Effect of ozonation on the mutagenicity of carcinogens in aqueous solution. Environ. Mutagen. 1982, 4(4):469.
74. Fernández L.A., Hernández C., Bataller M., Véliz E., López A., Ledea O., Padrón S. Cyclophosphamide degradation by advanced oxidation processes. Water Environ. J. 2010, 24(3):174.
75. The European Parliament and the Council of the European Union, Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to Medicinal products for human use, Available at: eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L: 2001:311:0067:0128:EN:PDF, Accessed on: 01/2013.
76. Escher B.I., Fenner K. Recent advances in environmental risk assessment of transformation products. Environ. Sci. Technol. 2011, 45(9):3835.
77. Isidori M., Lavorgna M., Nardelli A., Parrella A., Previtera L., Rubino M. Ecotoxicity of naproxen and its phototransformation products. Sci. Total Environ. 2005, 348(1-3):93.
78. Isidori M., Nardelli A., Parrella A., Pascarella L., Previtera L. A multispecies study to assess the toxic and genotoxic effect of pharmaceuticals: furosemide and its photoproduct. Chemosphere 2006, 63(5):785.
79. Isidori M., Parrella A., Pistillo P., Temussi F. Effects of ranitidine and its photoderivatives in the aquatic environment. Pharmaceutical products in the environment: trends toward lowering presence and impact. Environ. Int. 2009, 35(5):821.
80. Cheh A.M., Skochdopole J., Koski P., Cole L. Nonvolatile mutagens in drinking water: production by chlorination and destruction by sulfite. Science 1980, 207(4426):90.
81. J.D. Owusu-Yaw, Reactions of aqueous chlorine and chlorine dioxide with L-trytophan: genotoxicity studies and identification of some genotoxic reaction products, PHD, University of Florida, 1989.
82. Schenck K.M., Wymer L.J., Lykins B.W., Clark R.M. Application of a Finnish mutagenicity model to drinking waters in the U.S. Chemosphere 1998, 37(3):451.
83. Gartiser S., Hafner C., Kronenberger-Schäfer K., Happel O., Trautwein C., Kümmerer K. Approach for detecting mutagenicity of biodegraded and ozonated pharmaceuticals, metabolites and transformation products from a drinking water perspective. Environ. Sci. Pollut. Res. Int. 2012, 19(8):3597.
84. Vasquez M.I., Garcia-Käufer M., Hapeshi E., Menz J., Kostarelos K., Fatta-Kassinos D., Kümmerer K. Chronic ecotoxic effects to Pseudomonas putida and Vibrio fischeri, and cytostatic and genotoxic effects to the hepatoma cell line (HepG2) of ofloxacin photo(cata)lytically treated solutions. Sci. Total Environ. 2013, 450-451(0):356.
85. Garcia-Käufer M., Haddad T., Bergheim M., Gminski R., Gupta P., Mathur N., Kümmerer K., et al. Genotoxic effect of ciprofloxacin during photolytic decomposition monitored by the in vitro micronucleus test (MNvit) in HepG2 cells. Environ. Sci. Pollut. Res. 2012, 19(5):1719-1727.
86. Neuwoehner J., Zilberman T., Fenner K., Escher B.I. QSAR-analysis and mixture toxicity as diagnostic tools: influence of degradation on the toxicity and mode of action of diuron in algae and daphnids. Aquat. Toxicol. 2010, 97(1):58.
87. Mahmoud W.M.M., Toolaram A.P., Menz J., Leder C., Schneider M., Kümmerer K. Identification of phototransformation products of thalidomide and mixture toxicity assessment: an experimental and quantitative structural activity relationships (QSAR) approach. Water Res. 2014, 49:11-22.
88. R. Serafimova, M.F. Gatnik, A. Worth, Review of QSAR Models and Software Tools for Predicting Genotoxicity and Carcinogenicity JRC Scientific and Technical Report, 2010, European Union.
89. OECD Guidelines for Testing Chemicals Section 3 Degradation and Accumulation, OECD Publishing, 2012, Available at: http://www.oecd-ilibrary.org/environment/oecd-guidelines-for-the-testing-of-chemicals-section-3-degradation-and-accumulation_2074577x, Accessed on: 03/2013.
90. Rücker C., Kümmerer K. Modeling and predicting aquatic aerobic biodegradation: a review from a user's perspective. Green Chem. 2012, 14(4):875-887.
91. Fatta-Kassinos D., Vasquez M.I., Kümmerer K. Transformation products of pharmaceuticals in surface waters and wastewater formed during photolysis and advanced oxidation processes - degradation, elucidation of byproducts and assessment of their biological potency. Chemosphere 2011, 85(5):693.
92. OSPAR Commission, Survey on Genotoxicity Test Methods for the Evaluation of Waste Water within Whole Effluent Assessment, 2002.
93. McCann J., Ames B.N. The Detection of carcinogens as mutagens in the salmonella/microsome test: assay of 300 chemicals: discussion. Proc. Natl. Acad. Sci. U.S.A. 1976, 73:950-954.
94. Purchase F.H., Longstaff E., Ashby J., Styles J.A., Anderson D., Lefevre P.A., Westwood F.R. An evaluation of 6 short-term tests for detecting organic chemical carcinogens. Br. J. Cancer 1978, 37:873-959.
95. Walmsley R.M., Billinton N. How accurate is in vitro prediction of carcinogenicity?. Br. J. Pharmacol. 2011, 162(6):1250.
96. ISO 11350: Water Quality - Determination of the Genotoxicity of Water and Waste water - Salmonella/microsome Fluctuation Test (Ames fluctuation test), International Organization for Standardization, Geneva, Switzerland, 2012.
97. Escobar P.A., Kemper R.A., Tarca J., Nicolette J., Kenyon M., Glowienke S., Sawant S.G., et al. Bacterial mutagenicity screening in the pharmaceutical industry. Mutat. Res. 2013, 752(2):99.
98. Jolibois B. Hospital wastewater genotoxicity. Ann. Occup. Hyg. 2005, 50(2):189.
99. Jolibois B., Guerbet M. Efficacy of two wastewater treatment plants in removing genotoxins. Arch. Environ. Contam. Toxicol. 2005, 48(3):289.
100. Jolibois B., Guerbet M. Simplified protocol for evaluating the genotoxic risk of hospital wastewater. Environ. Toxicol. 2006, 21(2):141.
101. ISO 1829: Water Quality-Determination of Genotoxicity of Water and Waste water using the umu-test, International Organization for Standardization, Geneva, Switzerland, 2000.
102. Reifferscheid G., Grummt T. Environmental Challenges 2000, 67-79. Springer, Netherlands. S. Belkin (Ed.).
103. Kushwaha B., Pandey S., Sharma S., Srivastava R., Kumar R., Nagpure N., Dabas A., et al. In situ assessment of genotoxic and mutagenic potential of polluted river water in Channa punctatus and Mystus vittatus. Int. Aquat. Res. 2012, 4(1):16.
104. Bolognesi C., Hayashi M. Micronucleus assay in aquatic animals. Mutagenesis 2011, 26(1):205.